SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer
Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer.
Trial Details
- NCT ID
- NCT04861415
- Phase
- NA
- Sponsor
- Dr. Gerard Morton
- Status
- RECRUITING
- Cancer Type
- Prostate Cancer
- Interventions
- Sterotactic Body Radiotherapy
- Conventionally Fractionated Radiation
- Locations (sample)
- Toronto, Ontario, Canada|43.65333,-79.38389
Key Eligibility Criteria
- Age 18 or older
- Informed consent for treatment and study participation completed
- Pathologically proven diagnosis of prostate adenocarcinoma
- ECOG Performance Status 0-2
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →